| Project/Area Number |
25860789
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
NAKAMURA Shingen
HARADA Takeshi
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 多発性骨髄腫 / γδT細胞 / lenalidomide |
|---|
| Outline of Final Research Achievements |
Lenalidomide (Len) was able to expand γδ T cells more robustly in combination with HMB-PP than Zol from PBMCs from the majority of normal donors. However, Len alone did not show any significant effects on γδ T cell expansion and activation, suggesting a costimulatory role of Len on Zol or HMB-PP-primed γδ T cells. The surface expression of LFA-1, NKG2D, DNAM-1 and TRAIL were up-regulated in the expanded γδ T cells. Len in combination with either Zol or HMB-PP enhanced intracellular IFN-γ along with the surface NKG2D, suggesting robust induction of Th1-like γδ T cells by Len. Importantly, γδ T cells expanded with the combinatory treatments with Len and Zol or HMB-PP exerted potent cytotoxic activity against multiple myeloma (MM) cells. Interestingly, the expanded γδ T cells markedly suppressed the colony formation in RPMI8226 and KMS-11 cells, and decreased in size their side populations, suggesting targeting a drug-resistant clonogenic MM cells.
|
